

Please type a plus sign (+) inside this box →



Bat

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Application Number	09/715,965
		Filing Date	November 17, 2000
		First Named Inventor	Denholm
		Group Art Unit	1651
		Examiner Name	Meller, M.
		Attorney Docket Number	IT 106 (CPA)
Sheet	1	of	5

U.S. PATENT DOCUMENTS

## **FOREIGN PATENT DOCUMENTS**

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>				
MM	WO	96/01894		IBEX Technologies	01-25-1996		
✓	WO	96/01648		IBEX Technologies	01-25-1996		
✓	WO	96/08559		Cardiac CRC Nominees PTY, Ltd.	03-21-1996		

Examine  
Signature  Date Considered 9/3/02

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Approved for use through 10/31/99, OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete If Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)		Application Number 09/715,965	
		Filing Date November 17, 2000	
		First Named Inventor Denholm	
		Group Art Unit 1651	
		Examiner Name Meller, M.	
		Attorney Docket Number IT 106 (CPA)	
Sheet	2	of	5

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
W/M		CRUM, et al., "A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment," <i>Science</i> 230(4732): 1375-1378 (1985).
		CULP, et al., "Two functionally distinct pools of glycosaminoglycan in the substrate adhesion site of murine cells," <i>J. Cell Biol.</i> 79(3):788-801 (1978).
		DENHOLM, et al., "The effects of bleomycin on alveolar macrophage growth factor secretion," <i>Am J Pathol.</i> 134(2):355-63 (1989).
		DENHOLM, et al., "Chondroitinase AC inhibits tumor cell invasion, proliferation, and angiogenesis," <i>FASEB J</i> 14(4): A702 (2000).
		DENHOLM, et al., "Anti-tumor activities of chondroitinase AC and chondroitinase B: inhibition of angiogenesis, proliferation and invasion," <i>Eur J Pharmacol</i> 416(3): 213-221 (2000).
		FAASSEN, et. al., "A cell surface chondroitin sulfate proteoglycan, immunologically related to CD44, is involved in type I collagen-mediated melanoma cell motility and invasion," <i>J. Cell Biol.</i> 116(2):521-531 (1992).
		FAASSEN, et. al., "Cell surface CD44-related chondroitin sulfate proteoglycan is required for transforming growth factor-beta-stimulated mouse melanoma cell motility and invasive behavior on type I collagen," <i>J. Cell Science</i> 105(Pt 2):501-511 (1993).
		FOLKMAN, "Angiogenesis in cancer, vascular, rheumatoid and other disease," <i>Nat Med</i> 1(1):27-31 (1995).
		FOLKMAN, "Successful treatment of an angiogenic disease," <i>N. Engl. J. Med.</i> 320(18): 1211-1212 (1989).
V		FOLKMAN, "Tumor angiogenesis: therapeutic implications," <i>N. Engl. J. Med.</i> 285(21): 1182-1186 (1971).

Examiner's Signature		Date Considered	9/13/02
----------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →

 +

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 5

Application Number	09/715,965
Filing Date	November 17, 2000
First Named Inventor	Denholm
Group Art Unit	1651
Examiner Name	Meller, M.
Attorney Docket Number	IT 106 (CPA)

RECEIVED  
TECH CENTER 1600  
AUG 09 2002  
USPTO  
JC8  
AUG 06 2002  
PATENT & TRADEMARK OFFICE

### OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
/W/M/		FOLKMAN, et al., "Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone," <i>Science</i> 221(4612): 719-725 (1983).	
		FOLKMAN, et al., "Control of angiogenesis with synthetic heparin substitutes," <i>Science</i> 243(4897): 1490-1493 (1989).	
		FORRESTER, et al., "A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies," <i>J. Am. Coll. Cardiol.</i> 17(3):758-769 (1991).	
		GU, et. al., "Purification, characterization and specificity of chondroitin lyases and glycuronidase from Flavobacterium heparinum," <i>Biochem. J.</i> 312(Pt 2):569-577 (1995).	
		HENKE, et. al., "CD44-related chondroitin sulfate proteoglycan, a cell surface receptor implicated with tumor cell invasion, mediates endothelial cell migration on fibrinogen and invasion into a fibrin matrix," <i>J. Clin. Invest.</i> 97(11):2541-2552 (1996).	
		INGBER, et al., "Inhibition of angiogenesis through modulation of collagen metabolism," <i>J. Lab. Invest.</i> 59: 44-51 (1989).	
		INGBER, et al., "A possible mechanism for inhibition of angiogenesis by angiotropic steroids: induction of capillary basement membrane dissolution," <i>Endocrinol.</i> 119(4): 1768-1775 (1986).	
		INGBER, et al., "Mechanochemical switching between growth and differentiation during fibroblast growth factor-stimulated angiogenesis in vitro: role of extracellular matrix," <i>J. Cell. Biol.</i> 109(1): 317-330 (1989).	
		JACKSON et. al., "Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes," <i>Physiol. Rev.</i> 71(2):481-530 (1991).	
/V/		JIN-INCHI, et al., "Inhibition of experimental metastasis of murine Lewis lung carcinoma by an inhibitor of glucosylceramide synthase and its possible mechanism of action," <i>Cancer Res.</i> 50:6731-6737 (1990).	

Examiner's Signature

Date Considered

9/13/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 5

Complaint If Known

Application Number	09/715,965
Filing Date	November 17, 2000
First Named Inventor	Denholm
Group Art Unit	1651
Examiner Name	Meller, M.
Attorney Docket Number	IT 106 (CPA)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
<i>MW/M</i>	LIDA, et al., "Cell surface chondroitin sulfate proteoglycans in tumor cell adhesion, motility and invasion," <i>Sem. Cancer Biol.</i> 7:155-162, (1996).	
	LINHARDT, et al., "Polysaccharide lyases," <i>Appl. Biochem. Biotech.</i> 12(2): 135-176 (1986).	
	LINN et. al., "Isolation and characterization of two chondroitin lyases from <i>Bacteroides thetaiotaomicron</i> ," <i>J. Bacteriol.</i> 156(2):859-866 (1983).	
	MEYER, et al., "Mechanisms of tumour metastasis," <i>Eur. J. Cancer</i> 34(2):214-221 (1998).	
	MICHELACCI, et al., "Isolation and characterization of an induced chondroitinase ABC from <i>Flavobacterium heparinum</i> ," <i>Biochim. Biophys. Acta.</i> 923(2):291-301 (1987).	
	MURRAY, et al., "Purification and partial amino acid sequence of a bovine cartilage-derived collagenase inhibitor," <i>J. Biol. Chem.</i> 261(9): 4154-4159 (1986).	
	NAKAJIMA, et al., "Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines," <i>Science</i> 220(4597):611-613 (1983).	
	RICHARDSON, et al., "Transient morphological and biochemical alterations of arterial proteoglycan during early wound healing," <i>Exp. Mol. Pathol.</i> 58(2):77-95 (1993).	
	SATO, et al., "Submit structure of Chondroitinase ABC from <i>Proteus vulgaris</i> ," <i>Agric. Biol. Chem.</i> 50:1057-1059 (1986).	
<i>V</i>	TABAS, et al., "Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lipoprotein and lipoprotein(a) retention and macrophage foam cell formation," <i>J. Biol. Chem.</i> 268(27):20419-20432 (1993).	

Examiner's Signature: *MM. M* Date Considered: *9/13/02*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


+

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



**Substitute for form 1449A/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 5

Cmplt If Known	
Application Number	09/715,965
Filing Date	November 17, 2000
First Named Inventor	Denholm
Group Art Unit	1651
Examiner Name	Meller, M.
Attorney Docket Number	IT 106 (CPA)

RECEIVED  
TECH CENTER 1600  
AUG 09 2002  
2002

#### **OTHER ART - NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
MJM		TAKEUCHI, "Effect of chondroitinases on the growth of solid Ehrlich ascites tumour," <i>Brit J Cancer</i> 26(2): 115-119 (1972).	
		TROCHAN, et al., "Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesis in vitro," <i>Int. J. Cancer</i> 66:664-668 (1996).	
		VOLPI, "Fast moving and slow moving heparins, dermatan sulfate, and chondroitin sulfate: qualitative and quantitative analysis by agarose-gel electrophoresis," <i>Carbohydrate Res.</i> 247:263-278 (1993).	
		YEO, et al., "Alterations in proteoglycan synthesis common to healing wounds and tumors," <i>Am. J. Pathol.</i> 138(6):1437-1450 (1991).	
		ZAWADZKI, et al., "Blockade of metastasis formation by CD44-receptor globulin," <i>Int. J. Cancer</i> 75(6):919-924 (1998).	

Examiner's Signature \_\_\_\_\_ Date Considered 9/13/02

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND

ATL1 #532749 v1

IT 106 (CPA)  
077818/00008